Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

EYPT

+ Watchlist+ Portfolio

EyePoint, Inc.

Regulated industryPhysical productsTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$0.30
52-Week Range
$0.27 – $19.11
Market Cap
$30.95M
P/E (TTM)
—
EPS (TTM)
-3.97
Dividend Yield
0.00%
Advanced Metrics
Price/Book
0.23
PEG Ratio
—
Return on Equity
-221.92%
Return on Assets
-105.25%
Gross Margin
0.00%
Operating Margin
-13642.03%
Profit Margin
0.00%
Current Ratio
3.30
Debt/Equity
0.20
Total Debt
$21.76M
Free Cash Flow
$-169.81M
Revenue Growth
-21.70%
Earnings Growth
—
Enterprise Value
$-65.51M

Market Snapshot

About

EyePoint Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing therapeutics for serious eye disorders. The company's proprietary Durasert technology platform enables sustained, controlled release of medication directly into the eye, providing long-term therapeutic effect from a single administration. EyePoint markets YUTIQ for chronic non-infectious uveitis and DEXYCU for post-surgical inflammation, while developing additional product candidates for retinal diseases including wet age-related macular degeneration and diabetic macular edema. The company's approach aims to reduce treatment burden for patients with chronic eye conditions.